LncRNA LINC01123-mediated impaired fracture healing through miR-134-5p/XIAP axis

Delayed bone repair remains a significant orthopedic complication, causing persistent patient morbidity and high healthcare costs. Prior research has shown that long non-coding RNAs (lncRNAs) function as critical regulators in various physiological processes, including skeletal development and cellular differentiation. These molecular transcripts often act as decoys or scaffolds to modulate gene expression at the post-transcriptional level by sequestering microRNAs. While many lncRNAs have been linked to bone metabolism, the specific involvement of LINC01123 in osteogenic pathways remained poorly understood. Identifying the regulatory axes that govern osteoblast behavior is essential for developing targeted therapies for non-union fractures and other skeletal pathologies. This gap motivated the current investigation into how LINC01123 influences the molecular landscape of bone tissue regeneration.

This investigation characterizes the regulatory function of LINC01123 within the miR-134-5p/XIAP signaling axis during osteoblast maturation and mineralized matrix production. Researchers sought to determine if LINC01123 expression levels correlate with clinical outcomes in patients suffering from delayed fracture healing compared to healthy controls. The study evaluates how this specific lncRNA impacts the proliferative capacity and apoptotic rates of osteoblastic cells under controlled experimental conditions. Another objective involves verifying the direct binding interactions between LINC01123, microRNA-134-5p, and X-linked inhibitor of apoptosis protein (XIAP) using molecular biology techniques. The team aimed to establish whether LINC01123 could serve as a reliable diagnostic biomarker for predicting impaired osseous recovery in clinical practice. By manipulating these molecular components, the study clarifies the downstream effects on osteogenic marker expression, including Alkaline Phosphatase (ALP) and Osteocalcin (OCN).

Clinical samples from patients with delayed healing were analyzed using Real-time quantitative polymerase chain reaction (RT-qPCR) to quantify transcript levels of LINC01123 and miR-134-5p. The researchers employed a luciferase activity assay to confirm the competitive binding between LINC01123 and miR-134-5p within the cellular environment. Cellular proliferation was monitored through the cell counting kit-8 (CCK-8) protocol, while programmed cell death was measured via flow cytometry using specific apoptotic markers. Osteogenic potential was visualized using alizarin red staining assay to detect calcium deposition in the extracellular matrix during the differentiation process. Protein concentrations of key regulatory factors, such as XIAP, were determined through western blot assay to validate the RT-qPCR findings at the translational level. Receiver operating characteristic (ROC) curve analysis provided a statistical framework for assessing the diagnostic sensitivity and specificity of LINC01123 in clinical cohorts.

LINC01123 levels were significantly elevated in patients experiencing delayed fracture healing compared to those with normal recovery rates. During the progression of osteoblast differentiation, LINC01123 and XIAP expression decreased while miR-134-5p, ALP, OCN, and RUNX2 mRNA levels increased substantially. Overexpression of LINC01123 suppressed cell viability and triggered apoptosis while simultaneously reducing the expression of osteogenic biomarkers in cultured osteoblasts. Introduction of a miR-134-5p mimic effectively reversed the inhibitory effects that LINC01123 exerted on osteoblast behavior and mineralized nodule formation. Silencing XIAP was found to partially mitigate the negative impacts on differentiation caused by the inhibition of miR-134-5p, highlighting a complex regulatory hierarchy. The study confirmed that LINC01123 acts as a molecular sponge for miR-134-5p, thereby preventing the microRNA from downregulating its target, XIAP. The ROC analysis demonstrated that LINC01123 serves as a sensitive predictor for the occurrence of delayed osseous union in the studied patient population.

The findings indicate that LINC01123 acts as a negative regulator of bone healing by modulating the miR-134-5p/XIAP signaling pathway. This molecular axis provides a potential therapeutic target for interventions aimed at accelerating bone repair in clinical settings where healing is compromised. LINC01123 emerges as a promising prognostic marker that could help clinicians identify patients at risk for delayed fracture union early in the treatment process. Future research may focus on developing small molecule inhibitors or antisense oligonucleotides to suppress LINC01123 activity and promote osteogenesis. Enhancing the miR-134-5p/XIAP signaling cascade could offer a novel strategy for improving osteogenic differentiation in compromised bone environments. These results contribute to a deeper understanding of the non-coding RNA networks that influence skeletal regeneration and patient recovery after traumatic injury.